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Despitetheavailabilityofeﬀectivecombinationantiretroviraltherapy(cART),liverdiseaseisoneoftheleadingcausesofmorbidity
and mortality in Human Immunodeﬁciency Virus (HIV)-infected individuals, speciﬁcally, in the presence of viral hepatitis co-
infection. HIV, a single stranded RNA virus, can bind to and activate both Toll-like receptor (TLR)7 and TLR8 in circulating blood
mononuclearcells,butlittleisknownabouttheeﬀectofHIVonTLRsexpressedintheliver.HIVcandirectlyinfectcellsoftheliver
and HIV-mediated depletion of CD4+ T-cells in the gastrointestinal tract (GI tract) results in increased circulating lipopolysaccha-
ride (LPS), both of which may impact on TLR signaling in the liver and subsequent liver disease progression. The potential direct
and indirect eﬀects of HIV on TLR signaling in the liver will be explored in this paper.
1.Introduction
There are 33 million people infected with human immunod-
eﬁciency virus (HIV) and despite the availability of eﬀective
combination antiretroviral therapy (cART), life expectancy
inHIV-infectedpatientsremainsreduced.Liver-relatedmor-
talityisnowthecommonestcauseofnon-AIDSrelateddeath
in HIV-infected individuals on cART [1, 2]. Hepatitis B virus
(HBV) or hepatitis C virus (HCV) are the main causes of
liver disease in HIV-infected patients [3–6] with more rapid
liver disease progression and higher liver-related mortality
comparedwithindividualsinfectedwitheitherHBVorHCV
alone [3–6].
Recently, there have been increasing reports of liver dis-
ease in HIV-infected individuals in the absence of viral hep-
atitis [7–11]. These diseases largely include liver decompen-
sation with and without evidence of cirrhosis, nonalcoholic
liver disease (NALD) its more severe form nonalcoholic
steatohepatitis(NASH)andhepatocellularcancer(HCC)[7–
11]. Liver disease in HIV monoinfection has been signiﬁ-
cantlyassociatedwithhighHIVRNA,prolongedexposureto
cART as well as high body mass index (BMI), alcohol abuse
and increasing age [12–14].
This paper will discuss the likely direct and indirect
eﬀects of HIV on the innate immune system of the liver and
the potential contribution of these changes to liver disease in
the presence and absence of coinfection with hepatitis B and
C.
2.Toll-Like Receptor (TLR) Signallingand
the Liver
Toll-like receptors (TLRs) are pattern recognition recep-
tors that recognize pathogen-associated molecular patterns
(PAMPS). All TLRs have a cytosolic Toll/IL-1 receptor (TIR)
domain, which is responsible for signal transduction. Mye-
loid diﬀerentiation primary response gene 88 (MyD88) is the
main TIR-domain containing adapter molecules common to
allTLRsexceptTLR3.OtherTIR-domaincontainingadapter
moleculesincludeToll/IL-1receptordomaincontainingada-
ptor protein (TIRAP), Toll/IL-1 receptor domain containing
adaptor inducing interferon-beta (TRIF), and TRIF-related
adaptor molecule (TRAM) [15–17]( Table 1). Triggering
TLRs leads to activation of nuclear factor kappa B (NFκB)
resulting in an upregulation of proinﬂammatory cytokines
such as Tumour Necrosis Factor (TNF)-α, IL-1 and IL-6,2 Gastroenterology Research and Practice
Table 1: Known TLRs, ligands for these TLRs and the relevant signalling pathways.
TLR Recognises Signals through
1 Triacyl lipopeptides TIRAP-MyD88
2 Tri- and diacyl lipopeptides Mal/TIRAP-MyD88
3 dsRNA TRIF-MyD88 independent
4 LPS Mal/TIRAP-MyD88 & TRIF- MyD88 independent
5 Flagellin MyD88
6 Diacyl lipopeptides TIRAP-MyD88
7 ssRNA MyD88
8 ssRNA MyD88
9 CpG-DNA (bacterial origin and host derived apoptotic DNA fragments) MyD88
10 Undeﬁned Undeﬁned
and/or activation of Interferon Response Factors (IRFs)
which mediate transcription of Interferon (IFN) α and β and
subsequent downstream IFN-stimulated genes (ISGs). The
speciﬁcity of the TLR signalling response is critically regu-
lated by the various TIR-domain containing adapter mole-
cules that associate with the TLR directly or colocalise with
MyD88 [15–17].
MessengerRNA (mRNA) for all ten TLRs are expressed
in murine livers, and expression levels can be modulated
with corticosteroid treatment [18]. All ten human TLRs
(TLR 1-10) are expressed in the liver with diﬀerential exp-
ression depending on the cell type [17]. While the liver is
constantly exposed to bacterial microﬂora resident in the
gastrointestinal (GI) tract via the portal circulation the in-
ﬂammatory response is generally averted in the healthy liver
by modulation of the innate immune response, referred to
as “immune tolerance” (as reviewed by [19–21]). However,
under conditions of chronic bacterial exposure, TLR expres-
sion may be similarly altered [22].
Primary cultured hepatocytes express TLRs 1–10 al-
though the expression levels of TLRs 2–5 are very low and
may indicate immune tolerance or modulation of TLR exp-
ression in response to bacterial exposure [21].
Kupﬀer cells express TLRs 2, 3, 4, and 9 and are the ﬁrst
cell type in the liver to recognise translocated bacterial
products, such as lipopolysaccharide (LPS) from the GI tract
[21]. The physiological response of Kupﬀer cells to LPS in a
normal healthy person is also hyporesponsive or “tolerant”
[21]. Stimulation of TLR4 triggers a proinﬂammatory, pro-
ﬁbrotic response with production of chemokines CCL2, 3
and 4, adhesion molecules such as vascular cell adhesion
molecule 1(V-CAM 1) and intercellular adhesion molecule
1(I-CAM 1), transforming growth factor-β (TGFβ)a n du p -
regulation of TLR2 expression [23–25].
Hepatic stellate cells (HSC) also express TLRs 4 and 9
[23, 24]. The response of HSC to TLR9 ligation is proﬁbrotic
with enhanced collagen expression, but ligation may also
limit ﬁbrosis by inhibiting HSC migration [24].
Other main resident cell types in the liver also express
TLRs including TLR2–5 on human biliary epithelial cells
[26] and TLR4 on rat liver sinusoidal endothelial cells
(LSEC) [27]. Biliary epithelial cells and LSEC are generally
tolerant to LPS stimulation of TLR4 [26, 27]. Liver dendritic
cells (DC) and natural killer cells (NK) express a wide range
ofTLRsincludingTLR2,3,4,7,and9onDCsandTLR1,2,3,
4, 6, 7, and 9 on NK cells [17]. Unlike the resident monocytic
kupﬀer cells, DCs and NKs respond appropriately to TLR4
ligation under normal physiological conditions [17].
3.TLR Signalling,the Liverand HIV
3.1. Direct Eﬀects
3.1.1. HIV Infection of Liver Cells. Multiple cells in the liver
can be infected with HIV. HIV RNA has been detected in
primaryhumanhepatocytesbothexvivo[28–30]andinvitro
[31, 32], and we have recently shown that a number of hepa-
tocyte cell lines are permissive to low level HIV infection
invitro[33].KupﬀercellscanbeinfectedbyHIVinvivo[28–
30]andinvitrostudiessuggestthatHIVinfectionofprimary
Kupﬀer cells leads to productive infection [31, 32]. Binding
of HIV or glycoprotein (gp)120 to CXCR4 expressed on
HSCs led to an increase in CCL2 and other markers of HSC
activation including alpha smooth muscle actin (αSMA) and
TGF-β [34, 35].
3.1.2. Ligation of TLR7 and 8 by HIV. Given HIV RNA is also
a TLR7/8 ligand [36] and hepatocytes express either TLR7,
TLR8, or both, HIV may also directly activate TLRs in the
liver, although to date this has not been explored.
The eﬀects of HIV on TLR activation have been assessed
in mononuclear cells from blood. Ligation of TLR8 by HIV
RNA led to an increase in HIV replication and TNF-α pro-
duction in monocytes from blood via activation of the
MyD88-dependent NFκBp a t h w a y[ 37, 38]. Following HIV
infection of monocytes or stimulation with single stranded
(ss)HIV RNA the response to LPS stimulation was signiﬁ-
cantly enhanced with an increased production of proinﬂam-
matory cytokines including TNF-α, consistent with a loss of
“tolerance” [39]. Given Kupﬀer cells are of monocytic origin,
they may also respond to HIV through activation of TLR7/8
(Figure 1). Therefore, if there was any low level persistence of
HIVRNAintheliver,eveninthesettingofsuppressivecART,
this may potentially enhance the intrahepatic inﬂammatory
responses to LPS.Gastroenterology Research and Practice 3
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Figure 1: TLR signalling in the liver in the setting of HIV-HBV coinfection. HIV infection results in a signiﬁcant increase in circulating LPS,
potentially triggering an inﬂammatory response via activation of TLR4. ssHIV RNA can also activate TLR7 or 8 leading to an increase in
NF-κB which can drive both HIV replication and production of proinﬂammatory cytokines and chemokines. HBV binds to and inhibits sig-
nalling through Mal/TIRAP which would inhibit proinﬂammatory responses in the coinfected liver. Increased LPS and/or increased hepatic
apoptosis in the coinfected liver could also activate TLR9 resulting in further inﬂammation and HIV replication.
3.1.3. TLR9 and HIV. Other TLRs, such as TLR9, may also
contribute to eﬀects of HIV on the liver. Several studies have
now shown TLR9 polymorphisms are associated with rapid
disease progression [40, 41]a n dh i g h e rp e a kv i r a ll o a d[ 42]
suggesting TLR9 ligation events are important drivers of in-
ﬂammation during HIV infection.
TLR9 binds CpG-DNA of bacterial origin but more re-
cently, it has been shown that TLR9 can also be activated by
hepatocyte-derived apoptotic DNA fragments [24]. HIV can
induce hepatocyte apoptosis in vitro via binding of gp120 to
CXCR4 even in the absence of productive infection [43]. We
have recently shown that intrahepatic apoptosis is increased
in the setting of HIV-HBV coinfection using immunohis-
tochemistry of liver biopsies [44]. Signalling through TLR9
has also been shown to suppress HIV replication in ex vivo
lymphoid tissue blocks which correlated with production of
chemokines such as CXCL-10 and 12 and CCL 3, 4, and 5
[45]. Therefore, indirect eﬀects of HIV on TLR9 may also
contribute to liver disease in the setting of HIV infection.
3.1.4. HIV and Dendritic Cells. Dendritic cells provide an
important bridge between the innate and adaptive immune
systems. Plasmacytoid DC (pDC) in particular secrete type
I IFNs and proinﬂammatory cytokines following stimula-
tion with either TLR7 or TLR9 that in turn activate T cells.
During HIV infection, DC numbers and function are altered
[46]. HIV gp120 has been shown to inhibit the pDC
proinﬂammatoryresponsetoTLR9ligationinvitro[47],and
it has been demonstrated that ssHIV RNA activates pDCs via
TLR7/8ligationsuggestingamechanismwherebyHIVdrives
chronic immune activation [36]. However, the inﬂammatory
response of DCs from HIV-infected patients to TLR ligation
is unclear and has been described as either reduced [48, 49]
or unchanged [50, 51]. It is not currently known how HIV or
TLR ligation aﬀects DCs of the liver.
3.2. Indirect Eﬀects: HIV and LPS. HIV infection leads to a
signiﬁcant depletion of CD4 T cells in the GI tract which is
associated with a signiﬁcant increase in plasma LPS [52–54].
ItishypothesisedthattheincreasedLPSburdeninthesetting
of HIV infection leads to activation of the innate immune
response including monocyte/macrophages and DCs leading
to a signiﬁcant increase in IFN-α,I L - 6 ,a n dT N F - α [55].
There is also a signiﬁcant association between LPS and circu-
latingactivatedCD4andCD8Tcells(asmeasuredbyexpres-
sion of CD38 and HLA-DR) [53]. Exposure of peripheral
blood mononuclear cells (PBMCs) to agonists of TLRs 3,
4, 5, and 9 in vitro resulted in activation of both memory
and eﬀecter CD4 and CD8 T cells, consistent with LPS also
driving T-cell activation [56].
While it is currently unclear if elevated LPS plays a role
in liver disease progression in HIV monoinfection, it is
clear that elevated LPS is associated with, and in some
settingscontributesto,liverdiseaseprogression,forexample,4 Gastroenterology Research and Practice
alcoholic liver disease [57], nonalcoholic fatty liver disease,
nonalcoholic steatohepatitis [58–60], chronic hepatitis C
virus (HCV) infection [61, 62], chronic HBV [61], and HIV-
HCV coinfection [63]. Increased intestinal permeability in
HIV-HCV coinfected patients with cirrhosis was associated
with an increase in circulating LPS and monocyte activation
in blood and an increase in gene expression of hepatic TLR2
and TLR4 [22]. In addition, TNF-α expression was signiﬁ-
cantly correlated with hepatic inﬂammation as measured by
histology [64].
NFκB is a common downstream component of the TLR
signallingpathway.TheHIVpromoter,referredtoasthelong
terminal repeat (LTR), contains two NFκB binding sites, and
HIV transcription is signiﬁcantly increased following NFκB
binding [65]. This can be negatively regulated by nuclear
receptors peroxisome proliferator-activated receptor gamma
(PPARγ)a n dl i v e rXr e c e p t o r( L X R )[ 66]. Several studies
have shown that TLR activation by microbial products such
asLPSorﬂagellinenhancesHIVreplicationviaanincreasein
NFκB[45,67],therefore,apositivefeedbackmechanismmay
exist wherebyelevatedcirculating LPS drives HIV replication
whichmaydrivefurtherCD4T-celldepletioninturndriving
further increases in LPS (Figure 1).
StrategiesthattargetimmuneactivationinHIVinfection
might also be potentially beneﬁcial in the management of
liver disease the setting of HIV infection. Amongst many
antiactivation approaches that are currently being evaluated,
hydroxychloroquine,a drug used to treatinﬂammatory arth-
ritis, shows the most promise. Hydroxychloroquine reduces
endosomal TLR signalling and has recently been evaluated
in HIV-infected patients with reduced CD4 T-cell recovery
[68]. In this study, hydroxychloroquine led to a signiﬁcant
decrease in plasma LPS and multiple other markers of
immuneactivationandalsoledtoenhancedCD4T-cellreco-
very [68]. Further work is still required to better under-
stand whether reducing immune activation in HIV-infected
patients on cART will have an eﬀect on liver disease out-
comes.
4.TLR SignallinginHIV-HBVCoinfection:
Potential Interactions
Onaverage,10%ofpatientsinfectedwithHIVarecoinfected
with hepatitis B virus. With the introduction of cART, which
alsoincludes agentsactiveagainstboth HIVandHBV(HBV-
activeHAART),liver-relatedmortalityrateshavereduced[1]
but total and liver-related mortality still remain signiﬁcantly
elevated in HIV-HBV coinfected patients [6, 69].
InamousemodelofHBVinfection,activationofTLRs3,
4, 5, 7, or 9 suppressed HBV replication [70] and in another
study activation of TLR3 and TLR4 suppressed HBV rep-
licationviatheMyD88-independentpathway[71].Likemost
successful persistent viruses, HBV has evolved to adapt and
even subvert the host innate immune response.
4.1. HBV and TLR2 and TLR4. Previous work by ourselves
and others has shown that in chronic HBV monoinfec-
tion, TLR2 expression was downregulated on primary cir-
culating monocytes in chronic HBV infection compared to
uninfected controls [72–74]. Compared to HBeAg-negative
patients, HBeAg positive patients had lower expression of
TLR2 on monocytes, hepatocytes and kupﬀer cells [74]. This
was associated with a decrease in TNF-α expression when
either TLR4 or TLR2 was activated in vitro [74]. Most
recently, in an hepatocyte cell line, we have shown that
HBeAg binds to TIR-domain containing adapter-inducing
interferon (TRIF)-related adapter molecule (TRAM) and
MyD88-adapter like/Toll/IL-1 receptor domain containing
adapter protein (Mal/TIRAP) to eﬀectively inhibit signalling
through TLR2 and TLR4 which may represent another strat-
egy for HBV to evade the innate immune response [75].
In HIV-HBV coinfection, it is plausible that chronic ex-
posure to elevated LPS could contribute to a loss of tolerance
in TLR4 signalling in the liver. In combination with an im-
paired TLR2 signalling response mediated by HBV, the
TRIF-dependent IFN response might be further enhanced
(Figure 1). These interactions warrant further investigation
using in vitro model systems.
4.2. HBV and TLR9. HBV has also been shown to impair
TLR9 signalling in plasmacytoid DCs (pDCs) leading to re-
duced IFN-α production [76] which may be another mecha-
nism for evasion of the immune system. TLR9 expression is
increased in patients with chronic HBV compared to unin-
fected controls, and TLR9 expression signiﬁcantly correlates
with HBV DNA levels in plasma [77], suggesting a link bet-
ween TLR9 expression and viral replication. Given the direct
and indirect eﬀects of HIV on TLR9, it is possible that, in the
setting of HIV-HBV coinfection, TLR9 signalling in the liver
by both HIV and HBV could result in an increase in chemo-
kine production and a proinﬂammatory response.
5.TLR SignallinginHIV-HCVCoinfection:
Potential Interactions
The role of TLR signalling in HCV infection has been
reviewed elsewhere [23]. In brief, HCV has adapted multiple
methods of evading the host innate immune response by
downregulating signalling through TLRs 2, 4, 7, and 9 by
binding to and interfering with MyD88 and TRIF in multiple
cell types including hepatocytes, macrophages, and plasma-
cytoid (p)DCs [23]. HCV has also been shown to cleave
mitochondrial antiviral signalling protein (MAVS) which
formspartoftheviralsensingTLRsignallingcascade,inhibi-
ting IFN-α/β production, and transcription of antiviral ISGs
[78]. Recent studies have also shown a potential role for
TLR7 and 9 agonists in promoting clearance of HCV [79–
81]. This would suggest that HCV would contribute to a
reduction in the antiviral response in patients with HIV-
HCV coinfection.
We recently examined liver RNA and peripheral blood
monocytes from patients with HCV monoinfection (n =
46), HIV-HCV coinfection (n = 27), and HIV monoinfec-
tion (n = 20). We found that increasing Metavir inﬂam-
matory activity score was associated with increased hepatic
TLR2 and TLR4 mRNA as measured by reverse transcrip-
tase quantitative PCR (RT-qPCR) [64]. We also found a
signiﬁcant correlation between hepatic mRNA expression ofGastroenterology Research and Practice 5
TNF-α and TLR2 and TLR4. Interestingly, we found no dif-
ferences in TLR mRNA or protein expression between HCV
monoinfected, HIV-HCV coinfected, or HIV monoinfected
patients [64].
MonocytesfromHCVandHIV-HCVcoinfectedpatients
lack LPS tolerance and this lack of tolerance correlated with
liver inﬂammation, as measured by elevated intrahepatic
Kupﬀer cells activation markers CD163 and CD33 and ele-
vated circulating aspartate aminotransferase [61–63]. One
study suggested an impaired or tolerant response to TLR3
andTLR4inmonocytesfromHIV-HCV-infectedindividuals
when stimulated ex vivo, however, in this study high sponta-
neoussecretionofIL-6andTNF-αwereobserved,suggesting
a loss of tolerance in vivo [82]. Plasma levels of LPS in
HIV-HCV-coinfectedpatientsalsocorrelatedwithseverityof
cirrhosis [63], where patients with LPS in the upper quartile
(>42pg/mL) had a 19-fold higher risk of disease progression
compared to patients with LPS in the lower quartile.
6. Conclusion
HIV infection of the liver could potentially enhance TLR
signaling via a direct eﬀect of either the virus itself or HIV-
related proteins as well as via an indirect eﬀect on increased
circulating LPSlevels. Ourunderstanding of how HIVaﬀects
TLR function is largely derived from studies in blood. Fur-
therstudiesareneededtodeﬁnetheeﬀectsofHIVonexpres-
sion of TLR and functional TLR signaling in hepatic cells,
speciﬁcally in the presence of HBV and HCV coinfection.
T h e s es t u d i e sw i l lb ec r i t i c a lf o rt h ed e v e l o p m e n to fn o v e l
strategies to manage HIV-HBV and HIV-HCV coinfection
that extend beyond the use of antivirals alone.
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